<DOC>
	<DOC>NCT01705847</DOC>
	<brief_summary>This study is to determine the appropriate dosing regimen of GS-9820 in subjects with lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of GS-9820.</brief_summary>
	<brief_title>A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Previously treated recurrent Bcell iNHL, DLBCL, MCL, HL or CLL Measurable lymphadenopathy Requires therapy Recent history of a major nonlymphoid malignancy Evidence of ongoing infection Concurrent participation in another therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>chronic lymphocytic leukemia (CLL)</keyword>
	<keyword>non-Hodgkin lymphoma (NHL)</keyword>
	<keyword>Hodgkin lymphoma (HL)</keyword>
	<keyword>indolent non-Hodgkin lymphoma (iNHL)</keyword>
	<keyword>diffuse large B-cell lymphoma-activated B-cell (DLBCL-ABC)</keyword>
	<keyword>DLBCL-germinal center B-cell (GCB)</keyword>
	<keyword>mantle cell lymphoma (MCL)</keyword>
	<keyword>GS-9820</keyword>
	<keyword>phosphatidylinositol 3-kinase (PI3K)</keyword>
</DOC>